News & Events
Stay informed with the latest news, scientific advancements, company milestones, and industry insights as we continue to push the boundaries of research and innovation.

Upcoming Events
09.12.25 / CIMA Sciences + Rubio Metabolomics to Exhibit at the 2025 ADA 85th Scientific Sessions
The American Diabetes Association (ADA)’s 85th Scientific Sessions will be held in Chicago from June 20-23, 2025, bringing together leading experts to discuss the latest breakthroughs in diabetes research, prevention, and care. This year’s event will feature over 200 sessions, including cutting-edge clinical studies, symposia, and panel discussions, with a focus on topics like beta cell therapy, technology and innovation, and obesity management. Attendees can also participate in the Innovation Challenge, where startups pitch novel ideas to improve the lives of people with diabetes according to the American Diabetes Association. The conference will be available both in-person and on-demand.
Event Details:
- Date: June 20-23, 2025
- Location: McCormick Place Convention Center – Chicago, Illinois
- Booth #: 3612
11.07.25 / CIMA Sciences to Exhibit and Sponsor at the The Liver Meeting 2025
The Liver Meeting 2025, organized by the American Association for the Study of Liver Diseases (AASLD), will be held in Washington, DC, from November 7-11. This premier event brings together clinicians, researchers, and associates from around the globe to discuss the latest advancements in liver disease research, treatment, and transplantation. Attendees can expect to participate in scientific sessions, workshops, and networking opportunities. The meeting will also feature an exhibit hall with over 150 exhibitors showcasing cutting-edge products and services.
Event Details:
- Date: November 7-11, 2025
- Location: Walter E. Washington Convention Center – Washington D.C.
- Booth #: 761
- Poster Presentations:
- Maximizing the Diagnostic Yield of Non-Invasive Tests: Simultaneous Optimization of Key Performance Metrics for Fibrotic Liver Disease with a FIB-4 and MASEF (OWLiver) Strategy. Publication Number: 2077. Presentation date: Saturday 8th.
- Saroglitazar treatment reduced severity of MASLD phenotypes by lipidomic-based test OWLiver in subjects with MASLD in a 16-week phase 2 trial. Publication number: 4020. Presentation Date: Monday 10th. Poster of distinction.
Obesity, Diabetes and Liver Disease: Why Early Detection Changes Everything
Enhancing MASLD Risk Stratification: Integrating FIB-4 with the MASEF Score
Cima Sciences to exhibit at the 2025 AASLD The Liver Meeting
Cima Sciences to exhibit at the 85th ADA Scientific Sessions with Rubió Metabolomics
Cima Sciences responds to the call-to-action in the 2025 Consensus Report from the American Diabetes Association
Cima Sciences presents new data at The Liver Meeting 2024
Contact Us
300E Sonterra Blvd., Suite 1110
San Antonio, Texas 78258
Order OWLiver® Test
OWLiver® is a non-invasive blood test to assess MASLD. It analyzes a panel of biomarkers through metabolomics methodology.
